AEON Biopharma posts corporate presentation targeting $3.5B neurotoxin market

AEON Biopharma, Inc.

Corporate presentation made available on IR website, dated May 2026.
Presentation states AEON aims to disrupt a $3.5B neurotoxin market dominated by a single brand for over 30 years.
No specific financial results, clinical updates, or guidance changes disclosed in the filing.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.